Mersana Therapeutics (MRSN) News Today $0.62 +0.00 (+0.68%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Mersana Therapeutics CEO sells $2,618 in stockJanuary 18 at 8:26 PM | msn.comMersana Therapeutics chief development officer sells shares worth $3,444January 18 at 10:32 AM | msn.comMersana Therapeutics' chief accounting officer sells shares worth $2,061January 17 at 11:48 PM | msn.comMersana Therapeutics officer Timothy Lowinger sells $4,667 in stockJanuary 17 at 11:48 PM | msn.comMersana Therapeutics' chief legal officer sells $599 in stockJanuary 16, 2025 | msn.comMersana therapeutics VP Mandelia sells $1,128 in stockJanuary 16, 2025 | msn.comMersana Therapeutics (NASDAQ:MRSN) Given Outperform Rating at WedbushJanuary 13, 2025 | americanbankingnews.comBTIG Sticks to Its Buy Rating for Mersana Therapeutics (MRSN)January 12, 2025 | markets.businessinsider.comMersana Therapeutics Announces Positive Initial Clinical Data and FDA Fast Track Designation for Emiltatug Ledadotin (XMT-1660)January 12, 2025 | americanbankingnews.comBuy Rating for Mersana Therapeutics: Promising Efficacy and Safety of Emi-Le ADC Amid Stock Price VolatilityJanuary 11, 2025 | markets.businessinsider.comMersana Therapeutics selloff on data overdone, says BTIGJanuary 11, 2025 | markets.businessinsider.comMersana Therapeutics (NASDAQ:MRSN) Stock, Insider Trading ActivityJanuary 11, 2025 | benzinga.comMersana Therapeutics (NASDAQ:MRSN) Stock Quotes, Forecast and News SummaryJanuary 11, 2025 | benzinga.comWedbush Reaffirms Outperform Rating for Mersana Therapeutics (NASDAQ:MRSN)Wedbush restated an "outperform" rating and set a $4.00 target price (down previously from $7.00) on shares of Mersana Therapeutics in a research report on Friday.January 10, 2025 | marketbeat.comMersana Therapeutics, Inc.: Mersana Therapeutics Announces Additional FDA Fast Track Designation Granted to Emiltatug Ledadotin (XMT-1660)January 10, 2025 | finanznachrichten.deMersana Therapeutics: Promising Clinical Data and Strong Financial Position Justify Buy RatingJanuary 10, 2025 | markets.businessinsider.comMersana falls after early-stage trial data for lead cancer therapyJanuary 10, 2025 | msn.comWhy Is Cancer-Focused Mersana Therapeutics Stock Trading Lower On Friday?January 10, 2025 | finance.yahoo.comMersana Shares Rise on Advances With Breast-Cancer TreatmentJanuary 10, 2025 | marketwatch.comMersana Therapeutics Announces Additional FDA Fast Track Designation Granted to Emiltatug Ledadotin (XMT-1660)January 10, 2025 | markets.businessinsider.comMersana Therapeutics: FDA Grants Additional Fast Track Designation To XMT-1660January 10, 2025 | markets.businessinsider.comMersana Therapeutics Announces Additional FDA Fast Track Designation Granted to Emiltatug Ledadotin (XMT-1660)January 10, 2025 | globenewswire.comMersana Therapeutics Announces Positive Initial Clinical Data from Phase 1 Clinical Trial of Emiltatug Ledadotin (XMT-1660); Initiation of Expansion in Triple Negative Breast CancerJanuary 10, 2025 | globenewswire.comMersana Therapeutics, Inc. (NASDAQ:MRSN) Receives Consensus Rating of "Moderate Buy" from BrokeragesMersana Therapeutics, Inc. (NASDAQ:MRSN - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the eight analysts that are covering the company, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold rating, five have issued a buy ratDecember 28, 2024 | marketbeat.comMersana Therapeutics: We're About To Find Out If ADC Platform Is More TolerableDecember 19, 2024 | seekingalpha.comPromising Clinical Data and Valuation Support Mersana Therapeutics’ Buy RecommendationDecember 17, 2024 | markets.businessinsider.comXTX Topco Ltd Buys 225,823 Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN)XTX Topco Ltd raised its stake in shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN - Free Report) by 186.0% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 347,255 shares of the company'sDecember 13, 2024 | marketbeat.comMersana Therapeutics, Inc. (NASDAQ:MRSN) Shares Acquired by Jacobs Levy Equity Management Inc.Jacobs Levy Equity Management Inc. increased its stake in Mersana Therapeutics, Inc. (NASDAQ:MRSN - Free Report) by 104.5% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 993,046 shareDecember 8, 2024 | marketbeat.comAtom Investors LP Sells 340,774 Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN)Atom Investors LP lessened its position in shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN - Free Report) by 93.3% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 24,661 shares of the compaDecember 6, 2024 | marketbeat.comVerition Fund Management LLC Buys 1,292,200 Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN)Verition Fund Management LLC lifted its stake in shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN - Free Report) by 11,695.2% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,303,249 shares of the company's stock after acqDecember 6, 2024 | marketbeat.comMersana Therapeutics, Inc. (NASDAQ:MRSN) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesMersana Therapeutics, Inc. (NASDAQ:MRSN - Get Free Report) has earned an average rating of "Moderate Buy" from the eight ratings firms that are covering the firm, MarketBeat Ratings reports. Two analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued aDecember 3, 2024 | marketbeat.comAcuta Capital Partners LLC Has $2.27 Million Holdings in Mersana Therapeutics, Inc. (NASDAQ:MRSN)Acuta Capital Partners LLC cut its position in shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN - Free Report) by 27.8% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,200,000 shares of the companyNovember 28, 2024 | marketbeat.comLeerink Partnrs Issues Optimistic Estimate for MRSN EarningsMersana Therapeutics, Inc. (NASDAQ:MRSN - Free Report) - Equities research analysts at Leerink Partnrs upped their FY2024 EPS estimates for Mersana Therapeutics in a research note issued on Wednesday, November 13th. Leerink Partnrs analyst J. Chang now anticipates that the company will earn ($0.5November 18, 2024 | marketbeat.comWedbush Predicts Stronger Earnings for Mersana TherapeuticsMersana Therapeutics, Inc. (NASDAQ:MRSN - Free Report) - Analysts at Wedbush increased their FY2024 earnings estimates for Mersana Therapeutics in a report issued on Wednesday, November 13th. Wedbush analyst D. Nierengarten now expects that the company will post earnings of ($0.66) per share forNovember 18, 2024 | marketbeat.comBuy Rating for Mersana Therapeutics: Anticipated XMT-1660 Data as Key CatalystNovember 15, 2024 | markets.businessinsider.comMersana Therapeutics transferred with Buy rating at CitiNovember 15, 2024 | markets.businessinsider.comMersana Therapeutics (NASDAQ:MRSN) Coverage Initiated by Analysts at CitigroupCitigroup began coverage on shares of Mersana Therapeutics in a research note on Friday. They issued a "buy" rating and a $5.00 price objective on the stock.November 15, 2024 | marketbeat.comMersana Therapeutics Reports Q3 2024 Financial ResultsNovember 15, 2024 | markets.businessinsider.comTruist Financial Reaffirms Their Buy Rating on Mersana Therapeutics (MRSN)November 15, 2024 | markets.businessinsider.comMersana Therapeutics, Inc. (NASDAQ:MRSN) Q3 2024 Earnings Call TranscriptNovember 14, 2024 | msn.comMersana Therapeutics, Inc.: Mersana Therapeutics Provides Business Update and Announces Third Quarter 2024 Financial ResultsNovember 13, 2024 | finanznachrichten.deMersana Therapeutics Shares Climb 23% After 3Q Results Beat EstimatesNovember 13, 2024 | marketwatch.comThis Particular Biotech Stock Is Soaring On Two Key AnnouncementsNovember 13, 2024 | theglobeandmail.comMersana Therapeutics, Inc. (MRSN) Q3 2024 Earnings Call TranscriptNovember 13, 2024 | seekingalpha.comMersana Therapeutics Provides Business Update and Announces Third Quarter 2024 Financial ResultsNovember 13, 2024 | globenewswire.comMersana Therapeutics (MRSN) to Release Earnings on WednesdayMersana Therapeutics (NASDAQ:MRSN) will be releasing earnings before the market opens on Wednesday, November 13, Zacks reports.November 7, 2024 | marketbeat.comMersana Therapeutics to Host Third Quarter 2024 Conference Call on November 13, 2024November 6, 2024 | globenewswire.comSILVERARC CAPITAL MANAGEMENT, LLC Reduces Stake in Mersana Therapeutics IncOctober 15, 2024 | finance.yahoo.comMersana Therapeutics, Inc. (NASDAQ:MRSN) Receives Average Recommendation of "Moderate Buy" from BrokeragesMersana Therapeutics, Inc. (NASDAQ:MRSN - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the eight research firms that are presently covering the company, MarketBeat.com reports. Two research analysts have rated the stock with a hold rating, five have assigned a buy rOctober 14, 2024 | marketbeat.comMersana Therapeutics, Inc. (NASDAQ:MRSN) SVP Alejandra Carvajal Sells 5,598 SharesOctober 8, 2024 | insidertrades.com Get Mersana Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MRSN and its competitors with MarketBeat's FREE daily newsletter. Email Address MRSN Media Mentions By Week MRSN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MRSN News Sentiment▼-0.320.44▲Average Medical News Sentiment MRSN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MRSN Articles This Week▼133▲MRSN Articles Average Week Get Mersana Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MRSN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ATYR News Today ITOS News Today TRVI News Today DSGN News Today AVIR News Today AQST News Today RZLT News Today IMMP News Today CCCC News Today VYGR News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MRSN) was last updated on 1/20/2025 by MarketBeat.com Staff From Our PartnersBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredWarren Buffett Bets $40 Billion—You Can Get in for $20I call it "The Last Retirement Stock You'll Ever Need." Warren Buffett himself owns $40 billion of stock in...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredTrump’s Inauguration Shocker: “Move Your Cash Now”Just in the first week after Trump's win, many stocks jumped by double and even triple digits. But now he's...InvestorPlace | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mersana Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mersana Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MRSN Stock Alerts